



Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

November 2, 2023

CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at three upcoming investor conferences:

UBS Biopharma Conference 2023

5:00 pm ET on Wednesday, November 8, 2023.

6th Annual Evercore ISI HealthCONx Conference

3:00 pm ET on Wednesday, Nov 29, 2023.

Piper Sandler 35th Annual Healthcare Conference

1:00 pm ET on Thursday, November 30, 2023.

The fireside chats will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal [website](#) after the events.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's lead candidate, resmetirom, is a liver-directed oral therapy that is designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact

Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact

Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com



Source: Madrigal Pharmaceuticals, Inc.